Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ (2007) Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension and nitric oxide scavenging by cell-free hemoglobin. Blood 110:2166–2172. https://doi.org/10.1182/blood-2006-12-061697

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alhawiti NM (2021) Hemostatic alteration in sickle cell disease: pathophysiology of the hypercoagulable state. King Khalid Univ J Health Sci 6:1–5

Article  Google Scholar 

Mehta P, Mehta J (1980) Abnormalities of platelet aggregation in sickle cell disease. J Pediatr 96(2):209–213. https://doi.org/10.1016/s0022-3476(80)80804

Article  PubMed  CAS  Google Scholar 

Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E et al (1991) Pain in sickle cell disease. N Engl J Med 325:11–16. https://doi.org/10.1056/NEJM199107043250103

Article  PubMed  CAS  Google Scholar 

Wang WC, Lukens JN (1998) Sickle cell anemia and other sickling syndromes. In: Lee R, Lukens J, Greer JP, Rodgers GM, Paraskevas F, Foerster J (eds) Wintrobe’s clinical hematology. Williams & Wilkins, pp 1346–1397

Google Scholar 

Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ et al (2000) Predicting adverse outcomes in children with sickle cell disease: a report from the cooperative study (CSSCD). N Engl J Med 342:83–89. https://doi.org/10.1056/NEJM200001133420203

Article  PubMed  CAS  Google Scholar 

Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639–1644. https://doi.org/10.1056/NEJM199406093302303

Article  PubMed  CAS  Google Scholar 

Bashawri LA, Al-Mulhim AA, Ahmed MA, Bahnassi AA (2007) Platelet aggregation and physiological anticoagulants in sickle-cell disease. East Mediterr Health J 13(2):266–272 (PMID: 17684847)

PubMed  CAS  Google Scholar 

Gupta GK, Sarkar PD, Manyal R, Rajput MS (2022) Sickle cell disease: Assessment of hemostasis parameters in steady-state patients at tertiary care hospital, Indore. India Biomed Biotechnol Res J 6:81–85. https://doi.org/10.4103/bbrj.bbrj_162_21

Article  Google Scholar 

Chinawa JM, Emodi IJ, Ikefuna AN, Ocheni S (2013) Coagulation profile of children with sickle cell anemia in steady state and crisis attending the university of Nigeria teaching hospital, Ituku-Ozalla, Enugu. Niger J Clin Pract 16:159–163. https://doi.org/10.4103/1119-3077.110132

Article  PubMed  CAS  Google Scholar 

Dacie JV, Lewis SM (1994) Practical hematology, 8th edn. Churchill Livingstone, Edinburg, pp 320–325

Google Scholar 

Sarji KE, Eurenius K, Fullwood CO, Schraibman HB, Colwell JA (1979) Abnormalities of platelet aggregation in sickle cell anemia. Presence of a plasma factor inhibiting aggregation by ristocetin. Thromb Res 14(2–3):283–297. https://doi.org/10.1016/0049-3848(79)90238-x

Article  PubMed  CAS  Google Scholar 

Woulfe D, Yang J, Brass L (2001) ADP and platelets: the end of the beginning. J Clin Invest 107(12):1503–1505. https://doi.org/10.1172/JCI13361

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sixma JJ, van Zanten GH, Huizinga EG, van der Plas RM, Verkley M, Wu YP et al (1997) Platelet adhesion to collagen: an update. Thromb Haemost 78:434–438 (PMID: 9198192)

Article  PubMed  CAS  Google Scholar 

Lanza F, Beretz A, Stierlé A, Hanau D, Kubina M, Cazenave JP (1988) Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 255(6):H1276–H1288. https://doi.org/10.1152/ajpheart.1988.255.6.H1276

Article  PubMed  CAS  Google Scholar 

Leichtman DA, Brewer GJ (1977) A plasma inhibitor of ristocetin-induced platelet aggregation in patients with sickle hemoglobinopathies. Am J Hematol 2(3):251–258. https://doi.org/10.1002/ajh.2830020307

Article  PubMed  CAS  Google Scholar 

Buchanan GR, Holtkamp CA, Levy EN (1981) Racial differences in ristocetin-induced platelet aggregation. Br J Haematol 49(3):455–464. https://doi.org/10.1111/j.13652141.1981.tb07249.x

Article  PubMed  CAS  Google Scholar 

Raffini LJ, Niebanck AE, Hrusovsky J, Stevens A, Blackwood-Chirchir A, Ohene-Frempong K et al (2006) Prolongation of the prothrombin time and activated partial thromboplastin time in children with sickle cell disease. Pediatr Blood Cancer 47:589–593. https://doi.org/10.1002/pnc.20579

Article  PubMed  Google Scholar 

Kusfa IU, Aminu SM, Mamman AI, Hassan A, Babadoko AA, Mohammed MH et al (2018) Basic hemostatic parameters in adults with sickle cell anemia at Ahmadu Bello University Teaching Hospital. Zaria Nigeria Sahel Med J 21:157–161. https://doi.org/10.4103/smj.smj_2_17

Article  Google Scholar 

Kotila T, Adedapo K, Adedapo A, Oluwasola O, Fakunle E, Brown B (2005) Liver dysfunction in steady state sickle cell disease. Ann Hepatol 4:261–263 (PMID: 16432491)

Article  PubMed  CAS  Google Scholar 

Stathakis NE, Papayannis AG, Papayotas H, Scliros P, Gardakis C (1975) Hypercoagulability and hypofibrinolysis in sickle cell disease. Ann Hematol 31:355–364. https://doi.org/10.1007/BF01634001

Article  CAS  Google Scholar 

Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B et al (2016) A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med 374:625–635. https://doi.org/10.1056/NEJMoa1512021

Article  PubMed  CAS  Google Scholar 

Wun T, Soulieres D, Frelinger AL, Krishnamurti L, Novelli EM, Kutlar A et al (2013) A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 6:17. https://doi.org/10.1186/1756-8722-6-17

Article  PubMed  PubMed Central  CAS  Google Scholar 

Desai PC, Brittain JE, Jones SK, McDonald A, Wilson DR, Dominik R et al (2013) A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res 132:341–345. https://doi.org/10.1016/jthromres.2013.08.002

Article  PubMed  PubMed Central  CAS  Google Scholar 

Semple MJ, Al-Hasani SF, Kioy P, Savidge GF (1984) A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 51:303–306 (PMID: 6388012)

Article  PubMed  CAS  Google Scholar 

Zago MA, Costa FF, Ismael SJ, Tone LG, Bottura C (1984) Treatment of sickle cell diseases with aspirin. Acta Haematol 72:61–64. https://doi.org/10.1159/000206360

Article  PubMed  CAS  Google Scholar 

Noubouossie D, Key NS, Ataga KI (2016) Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev 30(4):245–256. https://doi.org/10.1016/j.blre.2015.12.003

Article  PubMed  CAS  Google Scholar 

Sparkenbaugh EM, Chantrathammachart P, Mickelson J, van Ryn J, Hebbel RP, Monroe DM et al (2014) Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 123:1747–1756. https://doi.org/10.1182/blood-2013-08-523936

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sparkenbaugh E, Pawlinski R (2013) Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol 162:3–14. https://doi.org/10.1111/bjh.12336

Article  PubMed  CAS  Google Scholar 

Arumugam PI, Mullins ES, Shanmukhappa SK, Monia BP, Loberg A, Shaw MA et al (2015) Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood 126:1844–1855. https://doi.org/10.1182/blood-2015-01-625707

Article  PubMed  PubMed Central  CAS  Google Scholar